Nana Tchabo, MD
Gynecologic Oncology · Morristown, NJNPI 1851508436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $527, more than ten times the $37 reported in 2019.
Across 86 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$370
- GSK$355
- Daiichi Sankyo Inc.$229
- Mirati Therapeutics, Inc.$153
- Eisai Inc.$82
- AstraZeneca$65
- plus $385 from 14 others
Across 35 payments — averaging $2185.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$72K
- AstraZeneca$3K
- Merck$2K
What the payments were for
- Food & beverage$1,639100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 23 | $370 |
| GSK | 15 | $355 |
| Daiichi Sankyo Inc. | 13 | $229 |
| Mirati Therapeutics, Inc. | 9 | $153 |
| Eisai Inc. | 5 | $82 |
| AstraZeneca(2 entities) | 4 | $65 |
| Kerecis Limited | 1 | $59 |
| Davol Inc. | 1 | $52 |
| Astellas Pharma US Inc | 2 | $41 |
| Incyte Corporation | 2 | $38 |
| Bayer | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| AbbVie | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$108
How this compares
$1,639 in reported general payments places this provider in the 60th percentile of 45 gynecologic oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $603 |
| Oxycodone Hcl | 24 | $113 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Morristown
- Daniel TobiasMorristown$11K
- Shannon TomitaMorristown$4K
- Allison WagreichMorristown$2K
- Paul HellerMorristown$632
- Sharyn LewinTeaneck$968K
- Scott RichardFlorham Park$84K
- Joyce VarughesePennington$16K
- James BosscherNeptune$13K
- Karim ElsahwiNeptune$11K
- William BurkeParamus$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.